Jim Simons
STLN

Jim Simons’s Starling Oncology, Inc. Common Stock STLN Stock Holding History

Jim Simons’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.77M Buy
902,809
+180,909
+25% +$555K ﹤0.01% 1701
2025
Q4 		$2.57M Sell
721,900
-28,600
-4% -$106K ﹤0.01% 1709
2025
Q3 		$2.62M Buy
750,500
+293,000
+64% +$1M ﹤0.01% 1901
2025
Q2 		$938K Buy
457,500
+209,900
+85% +$525K ﹤0.01% 2554
2025
Q1 		$282K Buy
247,600
+65,600
+36% +$50.8K ﹤0.01% 2944
2024
Q4 		$56.2K Buy
182,000
+12,000
+7% +$3.11K ﹤0.01% 3369
2024
Q3 		$55.6K Sell
170,000
-169,400
-50% -$70.2K ﹤0.01% 3334
2024
Q2 		$156K Buy
339,400
+199,300
+142% +$170K ﹤0.01% 3095
2024
Q1 		$221K Buy
140,100
+50,800
+57% +$96.6K ﹤0.01% 3195
2023
Q4 		$182K Buy
89,300
+17,000
+24% +$29.5K ﹤0.01% 3161
2023
Q3 		$101K Sell
72,300
-3,342
-4% -$3.46K ﹤0.01% 3243
2023
Q2 		$42K Sell
75,642
-56,858
-43% -$30.1K ﹤0.01% 3646
2023
Q1 		$90K Buy
+132,500
New +$169K ﹤0.01% 3519

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jim Simons's STLN Position: Q1 2026 in Review

Jim Simons increased its Starling Oncology, Inc. Common Stock (STLN) stake by 25% in Q1 2026, buying an estimated $555K and bringing the position to 902,809 shares worth $2.77M. The position accounts for ﹤0.01% of the portfolio, ranked #1701.

Jim Simons first reported a position in STLN in Q1 2023 and has held it in 13 quarters since. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Jim Simons held 902,809 shares of Starling Oncology, Inc. Common Stock worth $2.77M as of Q1 2026.
  • Jim Simons bought 180,909 Starling Oncology, Inc. Common Stock shares in Q1 2026, an estimated $555K.
  • Starling Oncology, Inc. Common Stock made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #1701 holding.
  • Jim Simons first reported a position in Starling Oncology, Inc. Common Stock in Q1 2023 and has held it in 13 quarters since.
  • 115 funds tracked by Wall St. Rank held Starling Oncology, Inc. Common Stock as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.